Published in Cytokine Growth Factor Rev on March 11, 2010
Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther (2011) 1.87
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev (2011) 1.26
Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res (2014) 1.23
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol (2011) 0.96
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer (2013) 0.96
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther (2011) 0.92
Current status of gene therapy for brain tumors. Transl Res (2012) 0.90
Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. CNS Oncol (2013) 0.88
Strategies in gene therapy for glioblastoma. Cancers (Basel) (2013) 0.87
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future (2016) 0.84
Retargeting of viruses to generate oncolytic agents. Adv Virol (2011) 0.84
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. Oncotarget (2015) 0.83
Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther (2011) 0.82
An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors. Mol Ther (2013) 0.80
Retargeting Strategies for Oncolytic Herpes Simplex Viruses. Viruses (2016) 0.80
Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus. J Virol (2013) 0.79
Engineering antiphagocytic biomimetic drug carriers. Ther Deliv (2013) 0.79
An intravenous stimulus package for oncolytic virotherapy. Mol Ther (2011) 0.77
Tumor-specific delivery of biologics by a novel T-cell line HOZOT. Sci Rep (2016) 0.75
Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther (2016) 0.75
Neurotransplantation: lux et veritas, fiction or reality? J Neurosurg Sci (2011) 0.75
Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses. Hum Gene Ther (2014) 0.75
Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus. Stem Cells Int (2017) 0.75
Mammalian neural stem cells. Science (2000) 16.09
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science (2004) 9.10
In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol (2001) 9.04
Angiogenesis in brain tumours. Nat Rev Neurosci (2007) 6.82
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A (2000) 5.49
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 5.47
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer (2007) 4.54
Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature (2005) 3.53
Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med (2000) 3.51
Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med (1995) 3.37
The therapeutic potential of neural stem cells. Nat Rev Neurosci (2006) 3.17
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell (2007) 2.70
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther (2008) 2.50
PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell (2008) 2.49
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med (2000) 2.24
Ischemia-induced neurogenesis of neocortical layer 1 progenitor cells. Nat Neurosci (2009) 2.21
Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther (2008) 2.10
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88
Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol (1998) 1.88
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med (2007) 1.74
Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells (2008) 1.74
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol Cancer Res (2008) 1.67
Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther (2003) 1.65
Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci (2005) 1.65
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res (2005) 1.63
Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther (2008) 1.61
Stem cells for ischemic brain injury: a critical review. J Comp Neurol (2009) 1.53
Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res (2009) 1.51
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther (2007) 1.46
Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells (2008) 1.46
Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther (2000) 1.45
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41
Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res (2009) 1.38
Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther (2008) 1.36
Development of adenovirus serotype 35 as a gene transfer vector. Virology (2003) 1.33
Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation (2006) 1.29
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther (1998) 1.29
Mesenchymal stem cells: lineage, plasticity, and skeletal therapeutic potential. Stem Cell Rev (2005) 1.29
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 1.26
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther (2007) 1.19
Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol (2008) 1.16
Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med (2007) 1.15
Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther (2009) 1.13
Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets (2007) 1.11
Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res (1999) 1.11
Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene (2008) 1.06
Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells (2005) 1.06
Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One (2009) 1.05
The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. J Cell Physiol (2009) 1.04
Novel compound enables high-level adenovirus transduction in the absence of an adenovirus-specific receptor. Hum Gene Ther (2005) 1.04
Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther (2007) 0.99
Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med (2006) 0.99
Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins. Proc Natl Acad Sci U S A (2007) 0.98
Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection. Cancer Lett (2008) 0.97
Development of transcriptionally regulated oncolytic adenoviruses. Oncogene (2005) 0.94
Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. Hum Gene Ther (2007) 0.90
Gene transfer to cervical cancer with fiber-modified adenoviruses. Int J Cancer (2004) 0.88
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther (2006) 0.87
Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy. Hum Gene Ther (2004) 0.87
Efficient adenoviral-mediated gene delivery into porcine mesenchymal stem cells. Mol Reprod Dev (2006) 0.86
Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses. J Gene Med (2007) 0.84
Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther (1995) 0.83
Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. Biochem Biophys Res Commun (2007) 0.83
Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther (2000) 0.81
Diagnostic criteria for schwannomatosis. Neurology (2005) 3.41
In vivo magnetic resonance imaging of transgene expression. Nat Med (2000) 3.35
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol (2009) 2.33
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther (1998) 2.13
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. J Theor Biol (2000) 1.94
Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model. Cell Prolif (2001) 1.86
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol (2011) 1.71
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res (2002) 1.62
Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases. J Biol Chem (1991) 1.60
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst (1998) 1.60
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol (2000) 1.54
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol (2001) 1.46
Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther (2001) 1.45
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol (1999) 1.43
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther (2006) 1.32
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther (2003) 1.31
Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta (1998) 1.31
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther (2006) 1.29
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol (2002) 1.29
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther (2008) 1.28
MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ (2009) 1.27
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 1.26
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res (2004) 1.19
MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci U S A (2012) 1.18
Extracellular vesicles and their convergence with viral pathways. Adv Virol (2012) 1.18
B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol (1999) 1.18
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther (2009) 1.16
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res (1994) 1.15
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol (1998) 1.14
Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev (2010) 1.13
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets (2007) 1.11
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
Cellular automaton of idealized brain tumor growth dynamics. Biosystems (2000) 1.10
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther (2013) 1.07
Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene (2008) 1.06
Emergence of a subpopulation in a computational model of tumor growth. J Theor Biol (2000) 1.06
Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg (2000) 1.06
Stereotactic radiofrequency thermal cingulotomy for obsessive compulsive disorder. J Neuropsychiatry Clin Neurosci (1990) 1.06
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J (2000) 1.06
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther (2011) 1.05
Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci (2003) 1.04
Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther (1998) 1.04
Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors. Hum Gene Ther (1994) 1.03
Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol (1995) 1.03
Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res (2011) 1.02
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther (1994) 1.02
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg (1996) 1.02
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther (2012) 1.02
Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther (1996) 1.02
Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res (2012) 1.01
Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Ther (1995) 1.01
Primary lymphoma of peripheral nerve: report of four cases. Am J Surg Pathol (2000) 1.00
Progress and prospects: gene therapy clinical trials (part 2). Gene Ther (2007) 1.00
Gene therapy for brain tumors. Brain Pathol (1995) 1.00
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res (2014) 1.00
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res (1999) 1.00
Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res (2013) 0.99
Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer. J Neurosurg (1999) 0.99
Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther (1994) 0.98
New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Hum Gene Ther (1998) 0.97
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res (2010) 0.97
Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol (2010) 0.97
Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg (1998) 0.95
Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector. Cancer Res (2001) 0.95
Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther (2004) 0.95
The subtemporal-transpetrous approach for excision of petroclival tumors. Am J Otol (1996) 0.94
Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov (2009) 0.94
Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin Cancer Res (2012) 0.92
Genetic strategies for brain tumor therapy. Cancer Gene Ther (2006) 0.92
Solitary sciatic nerve lymphoma as an initial manifestation of diffuse neurolymphomatosis. Case report and review of the literature. J Neurosurg (2000) 0.92
Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res (2000) 0.92
Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res (1995) 0.91
Cerebrovascular Biology and the various neural barriers: challenges and future directions. Neurosurgery (1999) 0.91
Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density. J Biol Chem (2013) 0.91
Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLoS One (2013) 0.90
Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol (1998) 0.88
Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse. J Neurooncol (1992) 0.87
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res (2001) 0.86
Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res (2002) 0.86
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther (1999) 0.86
Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Hum Gene Ther (1996) 0.85
The effect of ganciclovir on herpes simplex virus-mediated oncolysis. J Surg Res (1997) 0.85
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther (2006) 0.85
Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res (1993) 0.85
Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells. Adv Virol (2011) 0.85
Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Hum Gene Ther (1995) 0.85
Anti-angiogenic gene therapy in the treatment of malignant gliomas. Neurosci Lett (2012) 0.84
A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Adv Exp Med Biol (1998) 0.84
Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation. Cancer Gene Ther (2000) 0.84
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology (2012) 0.84
Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin Investig Drugs (2000) 0.84